Creating a database for melanoma in children and young adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to develop a comprehensive database for melanoma that includes cohorts of children, adolescents, and young adults. It will utilize retrospective data collection to analyze survival rates and sentinel lymph node positivity in these populations. The study will also adapt existing precision medicine algorithms for pediatric use and implement transfer learning techniques to enhance model accuracy with limited data. By integrating expert medical opinions, the study seeks to refine treatment approaches for melanoma in younger patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Melanoma patients of any age with histopathological confirmed melanoma

Exclusion Criteria:

* Not having a melanoma diagnosis
* Not having signed the informed consent
* Records prior to the year 2012 (as data might not accurately reflect current practices and treatment outcomes)

Where it's running

• Hospital Clínic de Barcelona (Dermatology service)
  Barcelona, Catalonia, Spain Recruiting

Study contacts

• Study coordinator: Susana Puig Sardà, MD, PhD
• Email: spuig@clinic.cat
• Phone: +34932275400

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using breath and skin tests to detect melanoma early

  This study is testing if a breath analyzer and a skin patch can help find advanced melanoma earlier by checking for certain chemicals in your breath and skin.

  Recruiting at 2 sites Fundacion Clinic per a la Recerca Biomédica · Barcelona and 2 other locations · NCT06605443

• PD-L1-targeted PET probe to map PD-L1 in solid tumors

  A PET tracer called 18F-F-PDL1-3 is being tested to see if it can detect PD-L1 expression in primary and metastatic tumors to help guide personalized treatment.

  Recruiting Phase 2 Peking University Cancer Hospital & Institute · Beijing · NCT07848243

• ctDNA-guided stopping of immune therapy in advanced melanoma

  This study tests whether stopping immune checkpoint inhibitor therapy after 12 months is safe for patients with advanced melanoma who have undetectable ctDNA and disease control.

  Recruiting Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT07830225

• ENPP1/cGAS and FAP in Solid Tumors in Vietnamese Patients

  This Vietnam-based study will test ENPP1, cGAS, and FAP expression in archived tumor samples from Vietnamese adults with solid cancers using immunohistochemistry.

  Recruiting at 2 sites Tam Anh Research Institute · Hanoi, Hanoi and 1 other locations · NCT07808164

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• NeoAdjuvant PD-1–Based Therapy in Resectable Advanced Melanoma (NASA)

  In people with resectable stage IIIB–IV melanoma, this study tests whether two infusions of pembrolizumab or a combination of ipilimumab plus nivolumab given before surgery can keep people alive at 2 years without needing additional adjuvant therapy.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07740941

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.